CoChat
Sign Up
Cited by 133

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Frontotemporal Dementia, Where Do We Stand? A Narrative Review

Antonioni, Annibale, Raho, Emanuela Maria, Lopriore, Piervito, Pace, Antonia Pia, Latino, Raffaela Rita, Assogna, Martina, Mancuso, Michelangelo, Gragnaniello, Daniela, Granieri, Enrico, Pugliatti, Maura, Di Lorenzo, Francesco, Koch, Giacomo·2023·International Journal of Molecular Sciences
DOI 10.3390/ijms241411732PMC PMC10380352
Open this paper in CoChat — free account

Abstract

Frontotemporal dementia (FTD) is a neurodegenerative disease of growing interest, since it accounts for up to 10% of middle-age-onset dementias and entails a social, economic, and emotional burden for the patients and caregivers. It is characterised by a (at least initially) selective degeneration of the frontal and/or temporal lobe, generally leading to behavioural alterations, speech disorders, and psychiatric symptoms. Despite the recent advances, given its extreme heterogeneity, an overview that can bring together all the data currently available is still lacking. Here, we aim to provide a state of the art on the pathogenesis of this disease, starting with established findings and integrating them with more recent ones. In particular, advances in the genetics field will be examined, assessing them in relation to both the clinical manifestations and histopathological findings, as well as considering the link with other diseases, such as amyotrophic lateral sclerosis (ALS). Furthermore, the current diagnostic criteria will be explored, including neuroimaging methods, nuclear medicine investigations, and biomarkers on biological fluids. Of note, the promising information provided by neurophysiological investigations, i.e., electroencephalography and non-invasive brain stimulation techniques, concerning the alterations in brain networks and neurotransmitter systems will be reviewed. Finally, current and experimental therapies will be considered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms241411732

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 37 references

Research works printed but not linked: 230

  1. Olney, 2017, Frontotemporal Dementia, Neurol. Clin., 35, 339, 10.1016/j.ncl.2017.01.008 · DOI · Paper page
  2. Mesulam, 2012, Quantitative classification of primary progressive aphasia at early and mild impairment stages, Brain, 135, 1537, 10.1093/brain/aws080 · DOI
  3. Brun, 2007, Identification and Characterization of Frontal Lobe Degeneration: Historical perspective on the development of FTD, Alzheimer Dis. Assoc. Disord., 21, S3, 10.1097/WAD.0b013e31815bf511 · DOI
  4. Logroscino, 2023, Incidence of Syndromes Associated with Frontotemporal Lobar Degeneration in 9 European Countries, JAMA Neurol., 80, 279, 10.1001/jamaneurol.2022.5128 · DOI · Paper page
  5. Erkkinen, 2018, Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases, Cold Spring Harb. Perspect. Biol., 10, a033118, 10.1101/cshperspect.a033118 · DOI
  6. Prince, 2012, Epidemiology of Dementias and Alzheimer’s Disease, Arch. Med. Res., 43, 600, 10.1016/j.arcmed.2012.11.003 · DOI
  7. Dick, 2016, Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes, Neurology, 86, 1736, 10.1212/WNL.0000000000002638 · DOI
  8. Neumann, 2007, TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions, J. Neuropathol. Exp. Neurol., 66, 177, 10.1097/01.jnen.0000248554.45456.58 · DOI
  9. Seeley, 2019, Behavioral Variant Frontotemporal Dementia, Contin. Lifelong Learn. Neurol., 25, 76, 10.1212/CON.0000000000000698 · DOI
  10. Gazzina, 2017, Clinical and biological phenotypes of frontotemporal dementia: Perspectives for disease modifying therapies, Eur. J. Pharmacol., 817, 76, 10.1016/j.ejphar.2017.05.056 · DOI
  11. Piguet, 2020, Frontotemporal dementias: Main syndromes and underlying brain changes, Curr. Opin. Neurol., 33, 215, 10.1097/WCO.0000000000000792 · DOI
  12. Sheelakumari, 2020, Neuroanatomical correlates of apathy and disinhibition in behavioural variant frontotemporal dementia, Brain Imaging Behav., 14, 2004, 10.1007/s11682-019-00150-3 · DOI
  13. Warren, 2013, Frontotemporal dementia, BMJ, 347, f4827, 10.1136/bmj.f4827 · DOI · Paper page
  14. Hodges, 2018, Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review, J. Alzheimer’s Dis., 62, 1467, 10.3233/JAD-171087 · DOI
  15. Convery, 2019, Review: Clinical, genetic and neuroimaging features of frontotemporal dementia, Neuropathol. Appl. Neurobiol., 45, 6, 10.1111/nan.12535 · DOI
  16. Pijnenburg, 2019, Von Economo neurons are part of a larger neuronal population that are selectively vulnerable in C9orf72 frontotemporal dementia, Neuropathol. Appl. Neurobiol., 45, 671, 10.1111/nan.12558 · DOI
  17. Manes, 2012, Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, 1354, 10.1212/WNL.0b013e3182518375 · DOI
  18. Hsieh, 2011, Neural basis of music knowledge: Evidence from the dementias, Brain, 134, 2523, 10.1093/brain/awr190 · DOI
  19. Finger, 2016, Frontotemporal Dementias, Contin. Lifelong Learn. Neurol., 22, 464, 10.1212/CON.0000000000000300 · DOI
  20. Thompson, 2005, Qualitative neuropsychological performance characteristics in frontotemporal dementia and Alzheimer’s disease, J. Neurol. Neurosurg. Psychiatry, 76, 920, 10.1136/jnnp.2003.033779 · DOI
  21. Pennington, 2011, Neural Correlates of Episodic Memory in Behavioral Variant Frontotemporal Dementia, J. Alzheimer’s Dis., 24, 261, 10.3233/JAD-2011-101668 · DOI
  22. Rascovsky, 2011, Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 2456, 10.1093/brain/awr179 · DOI · Paper page
  23. Valverde, 2009, A short neuropsychologic and cognitive evaluation of frontotemporal dementia, Clin. Neurol. Neurosurg., 111, 251, 10.1016/j.clineuro.2008.10.012 · DOI
  24. Cosentino, 2006, How does the brain support script comprehension? A study of executive processes and semantic knowledge in dementia, Neuropsychology, 20, 307, 10.1037/0894-4105.20.3.307 · DOI
  25. Possin, 2012, The Frontal-Anatomic Specificity of Design Fluency Repetitions and Their Diagnostic Relevance for Behavioral Variant Frontotemporal Dementia, J. Int. Neuropsychol. Soc., 18, 834, 10.1017/S1355617712000604 · DOI
  26. Kumfor, 2012, Disturbance of Emotion Processing in Frontotemporal Dementia: A Synthesis of Cognitive and Neuroimaging Findings, Neuropsychol. Rev., 22, 280, 10.1007/s11065-012-9201-6 · DOI
  27. Bertoux, 2011, Social Cognition and Emotional Assessment differentiates frontotemporal dementia from depression, J. Neurol. Neurosurg. Psychiatry, 83, 411, 10.1136/jnnp-2011-301849 · DOI · Paper page
  28. McDonald, 2014, The ecological validity of TASIT: A test of social perception, Neuropsychol. Rehabil., 14, 285, 10.1080/09602010343000237 · DOI
  29. Hodges, 2010, Semantic dementia: Demography, familial factors and survival in a consecutive series of 100 cases, Brain, 133, 300, 10.1093/brain/awp248 · DOI
  30. Younes, 2020, Neuropsychiatric Aspects of Frontotemporal Dementia, Psychiatr. Clin. N. A., 43, 345, 10.1016/j.psc.2020.02.005 · DOI
  31. Botha, 2019, Primary Progressive Aphasias and Apraxia of Speech, Contin. Lifelong Learn. Neurol., 25, 101, 10.1212/CON.0000000000000699 · DOI · Paper page
  32. Bott, 2014, Frontotemporal dementia: Diagnosis, deficits and management, Neurodegener. Dis. Manag., 4, 439, 10.2217/nmt.14.34 · DOI
  33. Rabinovici, 2010, Frontotemporal Lobar Degeneration: Epidemiology, pathophysiology, diagnosis and management, CNS Drugs, 24, 375, 10.2165/11533100-000000000-00000 · DOI
  34. Harris, 2019, Neuropsychological differentiation of progressive aphasic disorders, J. Neuropsychol., 13, 214, 10.1111/jnp.12149 · DOI · Paper page
  35. Mesulam, 2009, Neurology of anomia in the semantic variant of primary progressive aphasia, Brain, 132, 2553, 10.1093/brain/awp138 · DOI
  36. Shim, 2012, Anatomic, clinical, and neuropsychological correlates of spelling errors in primary progressive aphasia, Neuropsychologia, 50, 1929, 10.1016/j.neuropsychologia.2012.04.017 · DOI
  37. Butts, 2015, Neuropsychological Profiles Differ among the Three Variants of Primary Progressive Aphasia, J. Int. Neuropsychol. Soc., 21, 429, 10.1017/S1355617715000399 · DOI
  38. Ghosh, 2015, Clinical Subtypes of Frontotemporal Dementia, Am. J. Alzheimer’s Dis. Other Dementiasr., 30, 653, 10.1177/1533317513494442 · DOI
  39. Grossman, 2012, The non-fluent/agrammatic variant of primary progressive aphasia, Lancet Neurol., 11, 545, 10.1016/S1474-4422(12)70099-6 · DOI
  40. Marshall, 2018, Primary progressive aphasia: A clinical approach, J. Neurol., 265, 1474, 10.1007/s00415-018-8762-6 · DOI
  41. Weintraub, 2009, The Northwestern Anagram Test: Measuring Sentence Production in Primary Progressive Aphasia, Am. J. Alzheimer’s Dis. Other Dementiasr., 24, 408, 10.1177/1533317509343104 · DOI
  42. Graham, 2016, Lack of Frank Agrammatism in the Nonfluent Agrammatic Variant of Primary Progressive Aphasia, Dement. Geriatr. Cogn. Disord. Extra, 6, 407, 10.1159/000448944 · DOI
  43. Knibb, 2009, Making sense of progressive non-fluent aphasia: An analysis of conversational speech, Brain, 132, 2734, 10.1093/brain/awp207 · DOI
  44. Richard, 2005, Natural history of primary progressive aphasia, Neurology, 65, 887, 10.1212/01.wnl.0000175982.57472.84 · DOI
  45. Rosen, 2006, Behavioral features in semantic dementia vs other forms of progressive aphasias, Neurology, 67, 1752, 10.1212/01.wnl.0000247630.29222.34 · DOI
  46. Mesulam, 2003, The core and halo of primary progressive aphasia and semantic dementia, Ann. Neurol., 54, S11, 10.1002/ana.10569 · DOI
  47. Whitwell, 2017, Predicting clinical decline in progressive agrammatic aphasia and apraxia of speech, Neurology, 89, 2271, 10.1212/WNL.0000000000004685 · DOI
  48. Teichmann, 2013, Deciphering logopenic primary progressive aphasia: A clinical, imaging and biomarker investigation, Brain, 136, 3474, 10.1093/brain/awt266 · DOI
  49. Henry, 2010, The logopenic variant of primary progressive aphasia, Curr. Opin. Neurol., 23, 633, 10.1097/WCO.0b013e32833fb93e · DOI
  50. Rohrer, 2013, Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia, Brain Lang., 127, 121, 10.1016/j.bandl.2012.12.008 · DOI
  51. Harris, 2013, Classification and pathology of primary progressive aphasia, Neurology, 81, 1832, 10.1212/01.wnl.0000436070.28137.7b · DOI
  52. 2015, Right temporal lobe variant of frontotemporal dementia, J. Clin. Neurosci., 22, 1139, 10.1016/j.jocn.2014.12.022 · DOI
  53. Okada, 2018, Early-stage right temporal lobe variant of frontotemporal dementia: 3 years of follow-up observations, BMJ Case Rep., 29, bcr2018224431, 10.1136/bcr-2018-224431 · DOI
  54. Pozueta, 2019, Cognitive and Behavioral Profiles of Left and Right Semantic Dementia: Differential Diagnosis with Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease, J. Alzheimer’s Dis., 72, 1129, 10.3233/JAD-190877 · DOI
  55. Chan, 2009, The clinical profile of right temporal lobe atrophy, Brain, 132, 1287, 10.1093/brain/awp037 · DOI · Paper page
  56. Veronelli, 2017, Geschwind Syndrome in frontotemporal lobar degeneration: Neuroanatomical and neuropsychological features over 9 years, Cortex, 94, 27, 10.1016/j.cortex.2017.06.003 · DOI
  57. Joubert, 2006, The right temporal lobe variant of frontotemporal dementia: Cognitive and neuroanatomical profile of three patients, J. Neurol., 253, 1447, 10.1007/s00415-006-0232-x · DOI
  58. Kamminga, 2015, Differentiating between right-lateralised semantic dementia and behavioural-variant frontotemporal dementia: An examination of clinical characteristics and emotion processing, J. Neurol. Neurosurg. Psychiatry, 86, 1082, 10.1136/jnnp-2014-309120 · DOI · Paper page
  59. Borghesani, 2022, Frontotemporal dementia: A unique window on the functional role of the temporal lobes, Handb. Clin. Neurol., 187, 429, 10.1016/B978-0-12-823493-8.00011-0 · DOI
  60. Possin, 2010, Visual spatial cognition in neurodegenerative disease, Neurocase, 16, 466, 10.1080/13554791003730600 · DOI
  61. Kumfor, 2016, On the right side? A longitudinal study of left- versus right-lateralized semantic dementia, Brain, 139, 986, 10.1093/brain/awv387 · DOI · Paper page
  62. Fenoglio, 2018, Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer’s Disease and Frontotemporal Dementia, J. Alzheimer’s Dis., 62, 913, 10.3233/JAD-170702 · DOI
  63. Greaves, 2019, An update on genetic frontotemporal dementia, J. Neurol., 266, 2075, 10.1007/s00415-019-09363-4 · DOI · Paper page
  64. Wagner, 2021, Clinico-genetic findings in 509 frontotemporal dementia patients, Mol. Psychiatry, 26, 5824, 10.1038/s41380-021-01271-2 · DOI
  65. Borroni, 2011, Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration, Neurobiol. Aging, 32, 555.e1, 10.1016/j.neurobiolaging.2010.08.009 · DOI
  66. Barandiaran, 2012, Neuropsychological Features of Asymptomatic c.709-1G>A Progranulin Mutation Carriers, J. Int. Neuropsychol. Soc., 18, 1086, 10.1017/S1355617712000823 · DOI
  67. Floris, 2015, Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations, J. Neurol., 262, 375, 10.1007/s00415-014-7575-5 · DOI
  68. Mackenzie, 2016, Molecular neuropathology of frontotemporal dementia: Insights into disease mechanisms from postmortem studies, J. Neurochem., 138, 54, 10.1111/jnc.13588 · DOI
  69. Kurtishi, 2019, Cellular Proteostasis in Neurodegeneration, Mol. Neurobiol., 56, 3676, 10.1007/s12035-018-1334-z · DOI
  70. Balendra, 2018, C9orf72-mediated ALS and FTD: Multiple pathways to disease, Nat. Rev. Neurol., 14, 544, 10.1038/s41582-018-0047-2 · DOI · Paper page
  71. Beckers, 2021, C9orf72 ALS-FTD: Recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels, Autophagy, 17, 3306, 10.1080/15548627.2021.1872189 · DOI
  72. Lines, 2020, Modelling frontotemporal dementia using patient-derived induced pluripotent stem cells, Mol. Cell. Neurosci., 109, 103553, 10.1016/j.mcn.2020.103553 · DOI
  73. Gao, 2019, TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration, Mol. Cell. Neurosci., 100, 103396, 10.1016/j.mcn.2019.103396 · DOI
  74. Houghton, 2022, The Interplay Between Autophagy and RNA Homeostasis: Implications for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Front. Cell Dev. Biol., 10, 838402, 10.3389/fcell.2022.838402 · DOI
  75. Markovinovic, 2022, Disruption of ER-mitochondria tethering and signalling in C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia, Aging Cell, 21, e13549, 10.1111/acel.13549 · DOI
  76. Lynch, 1994, Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia- parkinsonism-amyotrophy complex, Neurology, 44, 1878, 10.1212/WNL.44.10.1878 · DOI
  77. Wang, 2016, Tau in physiology and pathology, Nat. Rev. Neurosci., 17, 22, 10.1038/nrn.2015.1 · DOI · Paper page
  78. Lecourtois, 2009, Partial deletion of the MAPT gene: A novel mechanism of FTDP-17, Hum. Mutat., 30, E591, 10.1002/humu.20979 · DOI
  79. Hannequin, 2010, Frontotemporal Dementia Phenotype Associated with MAPT Gene Duplication, J. Alzheimer’s Dis., 21, 897, 10.3233/JAD-2010-100441 · DOI
  80. Waheed, Z., Choudhary, J., Jatala, F.H., Noor, A., Zerr, I., and Zafar, S. (2023). The Role of Tau Proteoforms in Health and Disease. Mol. Neurobiol., 1–12. · DOI
  81. Boyarko, 2021, Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration, Front. Neurosci., 15, 702788, 10.3389/fnins.2021.702788 · DOI
  82. Snowden, 2015, Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations, Amyotroph. Lateral Scler. Front. Degener., 16, 497, 10.3109/21678421.2015.1074700 · DOI
  83. Benussi, 2015, Phenotypic Heterogeneity of Monogenic Frontotemporal Dementia, Front. Aging Neurosci., 7, 171, 10.3389/fnagi.2015.00171 · DOI
  84. Cruts, 2006, Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442, 920, 10.1038/nature05017 · DOI · Paper page
  85. Yu, 2010, The Spectrum of Mutations in Progranulin: A collaborative study screening 545 cases of neurodegeneration, Arch. Neurol., 67, 161, 10.1001/archneurol.2009.328 · DOI · Paper page
  86. Boland, 2022, Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis, Nat. Commun., 13, 5924, 10.1038/s41467-022-33500-9 · DOI · Paper page
  87. Bright, 2019, Neuroinflammation in frontotemporal dementia, Nat. Rev. Neurol., 15, 540, 10.1038/s41582-019-0231-z · DOI · Paper page
  88. Shao, 2022, Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration, Science, 378, 94, 10.1126/science.abq7860 · DOI
  89. Khan, 2012, Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion, J. Neurol. Neurosurg. Psychiatry, 83, 358, 10.1136/jnnp-2011-301883 · DOI · Paper page
  90. Ghetti, B., Wszolek, Z.K., Boeve, B.F., Spina, S., and Goedert, M. (2011). Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, John Wiley & Sons, Inc.. Chapter 14.
  91. Kovacs, 2009, TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea, Mov. Disord., 24, 1842, 10.1002/mds.22697 · DOI
  92. Borghero, 2011, A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD, Neurobiol. Aging, 32, 2327.e1, 10.1016/j.neurobiolaging.2011.06.009 · DOI
  93. Neumann, 2009, A new subtype of frontotemporal lobar degeneration with FUS pathology, Brain, 132, 2922, 10.1093/brain/awp214 · DOI · Paper page
  94. Watts, 2007, Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia, Clin. Genet., 72, 420, 10.1111/j.1399-0004.2007.00887.x · DOI
  95. Johnson, 2010, Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS, Neuron, 68, 857, 10.1016/j.neuron.2010.11.036 · DOI · Paper page
  96. Kovacs, 2014, Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration, Acta Neuropathol., 128, 397, 10.1007/s00401-014-1298-7 · DOI
  97. Bannwarth, 2014, A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement, Brain, 137, 2329, 10.1093/brain/awu138 · DOI
  98. Mol, 2021, Novel TUBA4A Variant Associated with Familial Frontotemporal Dementia, Neurol. Genet., 7, e596, 10.1212/NXG.0000000000000596 · DOI
  99. Williams, 2016, CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia, Nat. Commun., 7, 11253, 10.1038/ncomms11253 · DOI
  100. Mackenzie, 2017, TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics, Neuron, 95, 808, 10.1016/j.neuron.2017.07.025 · DOI
  101. Hallupp, 2020, CYLD is a causative gene for frontotemporal dementia—Amyotrophic lateral sclerosis, Brain, 143, 783, 10.1093/brain/awaa039 · DOI
  102. Sleiman, 2010, Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions, Nat. Genet., 42, 234, 10.1038/ng.536 · DOI · Paper page
  103. Finch, 2011, TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers, Neurology, 76, 467, 10.1212/WNL.0b013e31820a0e3b · DOI · Paper page
  104. Pottier, 2018, Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: A genome-wide association study, Lancet Neurol., 17, 548, 10.1016/S1474-4422(18)30126-1 · DOI · Paper page
  105. Brun, 1987, Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology, Arch. Gerontol. Geriatr., 6, 193, 10.1016/0167-4943(87)90021-5 · DOI
  106. Jones, 2018, In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms, Neurology, 90, e947, 10.1212/WNL.0000000000005117 · DOI · Paper page
  107. Neumann, 2019, Review: Neuropathology of non-tau frontotemporal lobar degeneration, Neuropathol. Appl. Neurobiol., 45, 19, 10.1111/nan.12526 · DOI · Paper page
  108. Perry, 2017, Clinicopathological correlations in behavioural variant frontotemporal dementia, Brain, 140, 3329, 10.1093/brain/awx254 · DOI · Paper page
  109. Uddin, 2022, Anterior insula as a gatekeeper of executive control, Neurosci. Biobehav. Rev., 139, 104736, 10.1016/j.neubiorev.2022.104736 · DOI
  110. Whitwell, 2009, Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations, Neurology, 73, 1058, 10.1212/WNL.0b013e3181b9c8b9 · DOI
  111. Beck, 2008, A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series, Brain, 131, 706, 10.1093/brain/awm320 · DOI
  112. Perry, 2013, Progranulin Mutations as Risk Factors for Alzheimer Disease, JAMA Neurol., 70, 774, 10.1001/2013.jamaneurol.393 · DOI
  113. Boeve, 2012, Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, 135, 765, 10.1093/brain/aws004 · DOI
  114. Mahoney, 2012, Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features, Brain, 135, 736, 10.1093/brain/awr361 · DOI
  115. Tan, 2014, Beyond the temporal pole: Limbic memory circuit in the semantic variant of primary progressive aphasia, Brain, 137, 2065, 10.1093/brain/awu118 · DOI
  116. Spinelli, 2017, Typical and atypical pathology in primary progressive aphasia variants, Ann. Neurol., 81, 430, 10.1002/ana.24885 · DOI · Paper page
  117. Gelpi, 2014, TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy, Neuropathol. Appl. Neurobiol., 40, 225, 10.1111/nan.12063 · DOI
  118. Chare, 2014, New criteria for frontotemporal dementia syndromes: Clinical and pathological diagnostic implications, J. Neurol. Neurosurg. Psychiatry, 85, 865, 10.1136/jnnp-2013-306948 · DOI
  119. Josephs, 2011, Neuropathological background of phenotypical variability in frontotemporal dementia, Acta Neuropathol., 122, 137, 10.1007/s00401-011-0839-6 · DOI
  120. Ulugut, 2021, Right temporal variant frontotemporal dementia is pathologically heterogeneous: A case-series and a systematic review, Acta Neuropathol. Commun., 9, 131, 10.1186/s40478-021-01229-z · DOI
  121. Rohrer, 2011, Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration, Brain, 134, 2565, 10.1093/brain/awr198 · DOI
  122. Lee, 2017, Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration, Acta Neuropathol., 134, 65, 10.1007/s00401-017-1679-9 · DOI
  123. Hillis, 2011, Classification of primary progressive aphasia and its variants, Neurology, 76, 1006, 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
  124. Tahmasian, 2016, Based on the Network Degeneration Hypothesis: Separating Individual Patients with Different Neurodegenerative Syndromes in a Preliminary Hybrid PET/MR Study, J. Nucl. Med., 57, 410, 10.2967/jnumed.115.165464 · DOI · Paper page
  125. Bejanin, 2020, Longitudinal structural and metabolic changes in frontotemporal dementia, Neurology, 95, e140, 10.1212/WNL.0000000000009760 · DOI · Paper page
  126. Narayanan, 2016, What can imaging tell us about cognitive impairment and dementia?, World J. Radiol., 8, 240, 10.4329/wjr.v8.i3.240 · DOI
  127. Hafkemeijer, 2015, Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study, NeuroImage Clin., 9, 418, 10.1016/j.nicl.2015.08.022 · DOI
  128. Filippi, 2017, Brain network connectivity differs in early-onset neurodegenerative dementia, Neurology, 89, 1764, 10.1212/WNL.0000000000004577 · DOI
  129. Buhour, 2017, Pathophysiology of the behavioral variant of frontotemporal lobar degeneration: A study combining MRI and FDG-PET, Brain Imaging Behav., 11, 240, 10.1007/s11682-016-9521-x · DOI
  130. Josephs, 2018, [18 F]AV-1451 tau-PET and primary progressive aphasia, Ann. Neurol., 83, 599, 10.1002/ana.25183 · DOI
  131. Rohrer, 2009, The heritability and genetics of frontotemporal lobar degeneration, Neurology, 73, 1451, 10.1212/WNL.0b013e3181bf997a · DOI · Paper page
  132. Rohrer, 2015, Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis, Lancet Neurol., 14, 253, 10.1016/S1474-4422(14)70324-2 · DOI · Paper page
  133. Panman, 2019, Gray and white matter changes in presymptomatic genetic frontotemporal dementia: A longitudinal MRI study, Neurobiol. Aging, 76, 115, 10.1016/j.neurobiolaging.2018.12.017 · DOI
  134. Zetterberg, 2019, Review: Fluid biomarkers for frontotemporal dementias, Neuropathol. Appl. Neurobiol., 45, 81, 10.1111/nan.12530 · DOI · Paper page
  135. Doroszkiewicz, J., Groblewska, M., and Mroczko, B. (2022). Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. Int. J. Mol. Sci., 23. · DOI
  136. Yoshimura, 2008, Stability of Pro-Gastrin-Releasing Peptide in Serum versus Plasma, Tumor Biol., 29, 224, 10.1159/000152940 · DOI
  137. Bolstad, 2013, Heterophilic antibody interference in immunometric assays, Best Pract. Res. Clin. Endocrinol. Metab., 27, 647, 10.1016/j.beem.2013.05.011 · DOI
  138. Apweiler, 2009, Approaching clinical proteomics: Current state and future fields of application in fluid proteomics, Clin. Chem. Lab. Med., 47, 724, 10.1515/CCLM.2009.167 · DOI
  139. Zetterberg, 2018, From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease, J. Alzheimer’s Dis., 64, S271, 10.3233/JAD-179926 · DOI
  140. Verde, F., Otto, M., and Silani, V. (2021). Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci., 15. · DOI
  141. Yuan, 2017, Neurofilaments and Neurofilament Proteins in Health and Disease, Cold Spring Harb. Perspect. Biol., 9, a018309, 10.1101/cshperspect.a018309 · DOI
  142. Barry, 2012, Expansion of Neurofilament Medium C Terminus Increases Axonal Diameter Independent of Increases in Conduction Velocity or Myelin Thickness, J. Neurosci., 32, 6209, 10.1523/JNEUROSCI.0647-12.2012 · DOI
  143. Gentil, 2015, Neurofilament dynamics and involvement in neurological disorders, Cell Tissue Res., 360, 609, 10.1007/s00441-014-2082-7 · DOI
  144. Bocquet, 2009, Neurofilaments Bind Tubulin and Modulate Its Polymerization, J. Neurosci., 29, 11043, 10.1523/JNEUROSCI.1924-09.2009 · DOI
  145. Yuan, 2018, Neurofilament light interaction with GluN1 modulates neurotransmission and schizophrenia-associated behaviors, Transl. Psychiatry, 8, 167, 10.1038/s41398-018-0194-7 · DOI
  146. Khalil, 2018, Neurofilaments as biomarkers in neurological disorders, Nat. Rev. Neurol., 14, 577, 10.1038/s41582-018-0058-z · DOI · Paper page
  147. Gaetani, 2019, Neurofilament light chain as a biomarker in neurological disorders, J. Neurol. Neurosurg. Psychiatry, 90, 870, 10.1136/jnnp-2018-320106 · DOI · Paper page
  148. Niikado, 2019, Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic, J. Gerontol. A Biol. Sci. Med. Sci., 74, 442, 10.1093/gerona/gly179 · DOI
  149. Mattsson, 2017, Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival, Amyotroph. Lateral Scler. Front. Degener., 18, 397, 10.1080/21678421.2017.1281962 · DOI
  150. Ljungqvist, 2017, Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study, J. Neurotrauma, 34, 1124, 10.1089/neu.2016.4496 · DOI
  151. Scherling, 2014, Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration, Ann. Neurol., 75, 116, 10.1002/ana.24052 · DOI · Paper page
  152. Meeter, 2018, Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers, Ann. Clin. Transl. Neurol., 5, 583, 10.1002/acn3.559 · DOI · Paper page
  153. Farahmand, 2014, CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival, Neurology, 83, 1945, 10.1212/WNL.0000000000001015 · DOI · Paper page
  154. Olsson, 2019, Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and Movement Disorders, JAMA Neurol., 76, 318, 10.1001/jamaneurol.2018.3746 · DOI
  155. Benussi, 2020, Diagnostic and prognostic value of serum NfL and p-Tau181in frontotemporal lobar degeneration, J. Neurol. Neurosurg. Psychiatry, 91, 960, 10.1136/jnnp-2020-323487 · DOI
  156. Wilke, 2016, Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum, J. Neurol. Neurosurg. Psychiatry, 87, 1270, 10.1136/jnnp-2015-312972 · DOI · Paper page
  157. Katisko, 2019, Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders, J. Neurol., 267, 162, 10.1007/s00415-019-09567-8 · DOI · Paper page
  158. Ljubenkov, 2018, Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory, Ann. Clin. Transl. Neurol., 5, 1250, 10.1002/acn3.643 · DOI · Paper page
  159. Alcolea, 2018, CSF sAPPβ, YKL-40, and NfL along the ALS-FTD spectrum, Neurology, 91, e1619, 10.1212/WNL.0000000000006383 · DOI
  160. Goossens, 2018, Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration, Alzheimer’s Res. Ther., 10, 31, 10.1186/s13195-018-0364-0 · DOI
  161. Cajanus, 2020, Serum neurofilament light chain in FTLD: Association with C9orf72, clinical phenotype, and prognosis, Ann. Clin. Transl. Neurol., 7, 903, 10.1002/acn3.51041 · DOI
  162. Gafson, 2020, Neurofilaments: Neurobiological foundations for biomarker applications, Brain, 143, 1975, 10.1093/brain/awaa098 · DOI
  163. Yuan, 2015, Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo, Mol. Psychiatry, 20, 986, 10.1038/mp.2015.45 · DOI
  164. Brettschneider, 2014, Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD), Acta Neuropathol., 127, 423, 10.1007/s00401-013-1238-y · DOI
  165. Jo, 2020, The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies, Exp. Mol. Med., 52, 1652, 10.1038/s12276-020-00513-7 · DOI
  166. Hasegawa, 2008, Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Ann. Neurol., 64, 60, 10.1002/ana.21425 · DOI · Paper page
  167. Feneberg, 2014, Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases, Amyotroph. Lateral Scler. Front. Degener., 15, 351, 10.3109/21678421.2014.905606 · DOI
  168. Kleinberger, 2016, sTREM 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers, EMBO Mol. Med., 8, 466, 10.15252/emmm.201506123 · DOI · Paper page
  169. Jamerlan, A.M., Shim, K.H., Youn, Y.C., Teunissen, C., An, S.S.A., Scheltens, P., and Kim, S. (2023). Increased oligomeric TDP-43 in the plasma of Korean frontotemporal dementia patients with semantic dementia. Alzheimer’s Dement., 1–8. · DOI
  170. Doke, 2023, Shapeshifter TDP-43: Molecular mechanism of structural polymorphism, aggregation, phase separation and their modulators, Biophys. Chem., 295, 106972, 10.1016/j.bpc.2023.106972 · DOI
  171. Petkau, 2014, Progranulin in neurodegenerative disease, Trends Neurosci., 37, 388, 10.1016/j.tins.2014.04.003 · DOI
  172. Petkau, 2012, Synaptic dysfunction in progranulin-deficient mice, Neurobiol. Dis., 45, 711, 10.1016/j.nbd.2011.10.016 · DOI
  173. Petkau, 2013, Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice, Neurobiol. Aging, 34, 2548, 10.1016/j.neurobiolaging.2013.04.019 · DOI
  174. Colombrita, 2012, TDP-43 and FUS RNA-binding Proteins Bind Distinct Sets of Cytoplasmic Messenger RNAs and Differently Regulate Their Post-transcriptional Fate in Motoneuron-like Cells, J. Biol. Chem., 287, 15635, 10.1074/jbc.M111.333450 · DOI
  175. Petoukhov, 2013, Activity-dependent secretion of progranulin from synapses, J. Cell Sci., 126, 5412
  176. Heinze, 2018, CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms?, Front. Neurol., 9, 504, 10.3389/fneur.2018.00504 · DOI
  177. Wilke, 2016, Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease, Curr. Alzheimer Res., 13, 654, 10.2174/1567205013666160314151247 · DOI
  178. Ghidoni, 2008, Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, 71, 1235, 10.1212/01.wnl.0000325058.10218.fc · DOI
  179. Shi, 2020, Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study, J. Nucl. Med., 61, 1814, 10.2967/jnumed.119.240325 · DOI
  180. Hellwig, 2019, Amyloid imaging for differential diagnosis of dementia: Incremental value compared to clinical diagnosis and [18F]FDG PET, Eur. J. Nucl. Med. Mol. Imaging, 46, 312, 10.1007/s00259-018-4111-3 · DOI · Paper page
  181. Struyfs, 2015, Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis, J. Alzheimer’s Dis., 45, 813, 10.3233/JAD-141986 · DOI
  182. Martorana, 2015, Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State, CNS Neurosci. Ther., 21, 921, 10.1111/cns.12476 · DOI
  183. Alcolea, 2017, CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration, Neurology, 89, 178, 10.1212/WNL.0000000000004088 · DOI · Paper page
  184. Farahmand, 2015, Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia, Brain, 138, 2716, 10.1093/brain/awv181 · DOI
  185. Foiani, 2018, Plasma tau is increased in frontotemporal dementia, J. Neurol. Neurosurg. Psychiatry, 89, 804, 10.1136/jnnp-2017-317260 · DOI · Paper page
  186. Ntymenou, S., Tsantzali, I., Kalamatianos, T., Voumvourakis, K.I., Kapaki, E., Tsivgoulis, G., Stranjalis, G., and Paraskevas, G.P. (2021). Blood Biomarkers in Frontotemporal Dementia: Review and Meta-Analysis. Brain Sci., 11. · DOI · Paper page
  187. Thijssen, 2020, Amyloid, pTau, NfL, and GFAP as biomarkers for Alzheimer’s disease, Alzheimer’s Dement., 16, e038179, 10.1002/alz.038179 · DOI
  188. Pereira, 2021, Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease, Brain, 144, 3505, 10.1093/brain/awab223 · DOI · Paper page
  189. Tan, 2023, Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition, J. Alzheimer’s Dis., 92, 573, 10.3233/JAD-221072 · DOI
  190. Foiani, 2019, Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: An elusive quest, J. Neurol. Neurosurg. Psychiatry, 90, 740, 10.1136/jnnp-2018-319266 · DOI
  191. Bridel, 2023, Clusters of co-abundant proteins in the brain cortex associated with fronto-temporal lobar degeneration, Alzheimer’s Res. Ther., 15, 59, 10.1186/s13195-023-01200-1 · DOI
  192. Oliviero, 2022, Editorial: Non-invasive Brain Stimulation for Neurodegenerative Disorders: From Investigation to Therapeutic Application, Front. Neurol., 13, 820942, 10.3389/fneur.2022.820942 · DOI
  193. Casula, 2023, Regional Precuneus Cortical Hyperexcitability in Alzheimer’s Disease Patients, Ann. Neurol., 93, 371, 10.1002/ana.26514 · DOI
  194. Picazio, 2020, Effects of Cerebellar Theta Burst Stimulation on Contralateral Motor Cortex Excitability in Patients with Alzheimer’s Disease, Brain Topogr., 33, 613, 10.1007/s10548-020-00781-6 · DOI
  195. Koch, 2021, Synaptic impairment: The new battlefield of Alzheimer’s disease, Alzheimer’s Dement., 17, 314, 10.1002/alz.12189 · DOI
  196. Murley, 2018, Neurotransmitter deficits from frontotemporal lobar degeneration, Brain, 141, 1263, 10.1093/brain/awx327 · DOI
  197. Murley, 2020, GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition, Brain, 143, 3449, 10.1093/brain/awaa305 · DOI
  198. Pierantozzi, 2004, Different TMS patterns of intracortical inhibition in early onset Alzheimer dementia and frontotemporal dementia, Clin. Neurophysiol., 115, 2410, 10.1016/j.clinph.2004.04.022 · DOI
  199. Pilato, 2006, In vivo cholinergic circuit evaluation in frontotemporal and Alzheimer dementias, Neurology, 66, 1111, 10.1212/01.wnl.0000204183.26231.23 · DOI
  200. Alberici, 2008, The contribution of TMS to frontotemporal dementia variants, Acta Neurol. Scand., 118, 275, 10.1111/j.1600-0404.2008.01017.x · DOI

200 of 230 shown

Cited by

Sorted by citations

See all 133

Metadata

Authors
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., Di Lorenzo, F., & Koch, G.
Affiliations
  • Unit of Clinical Neurology, Neurosciences and Rehabilitation Department, University of Ferrara, 44121 Ferrara, Italy
  • Neurological Institute, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
  • Institute of Radiology, Department of Medicine, University of Udine, University Hospital S. Maria della Misericordia, Azienda Sanitaria-Universitaria Friuli Centrale, 33100 Udine, Italy
  • Complex Structure of Neurology, Emergency Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
  • Centro Demenze, Policlinico Tor Vergata, University of Rome ‘Tor Vergata’, 00133 Rome, Italy
  • Nuerology Unit, Neurosciences and Rehabilitation Department, Ferrara University Hospital, 44124 Ferrara, Italy
  • Non Invasive Brain Stimulation Unit, Istituto di Ricovero e Cura a Carattere Scientifico Santa Lucia, 00179 Rome, Italy
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-07-21
Volume
24
Issue
14
Pages
11732
ISSN
1422-0067
DOI
10.3390/ijms241411732
PMC
PMC10380352
Cited by
133
References
37
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review